```html

Yellow Plaque on Skin (Xanthoma)

What is Yellow plaque on skin (xanthoma)?

A xanthoma (plural: xanthomas) is a benign, yellow‑orange to orange‑brown plaque, nodule, or papule that forms when cholesterol‑rich lipids accumulate within the skin’s macrophages (a type of immune cell). The word comes from the Greek “xanthos,” meaning yellow. Xanthomas are not infections or allergic reactions; they are a visual clue that something is happening with the body’s lipid metabolism, liver function, or immune system.

They most often appear on the elbows, knees, hands, feet, buttocks, eyelids (known as xanthelasma), and around the tendons. While the lesions themselves are harmless, they can signal underlying disorders that increase a person’s risk for cardiovascular disease, pancreatitis, or systemic inflammation.

Common Causes

Below are the most frequent conditions that lead to the development of xanthomas. Many of them involve elevated blood lipids, but some are unrelated to cholesterol and stem from metabolic or genetic issues.

• Familial Hypercholesterolemia (FH) – an inherited defect in LDL‑receptor function leading to very high LDL‑cholesterol.
• Familial Combined Hyperlipidemia – elevated LDL, VLDL, and triglycerides.
• Type III Hyperlipoproteinemia (Dysbetalipoproteinemia) – accumulation of remnants of VLDL/LDL (apoE2/E2 genotype).
• Familial Chylomicronemia Syndrome – severe hypertriglyceridemia due to lipoprotein lipase deficiency.
• Primary Biliary Cholangitis (formerly Primary Biliary Cirrhosis) – chronic liver disease that impairs cholesterol clearance.
• Non‑alcoholic Fatty Liver Disease (NAFLD) / NASH – can cause secondary hyperlipidemia and xanthomas.
• Diabetes mellitus (especially poorly controlled) – leads to mixed dyslipidemia and xanthoma formation.
• Nie​n‑Mendelian metabolic disorders such as:
  • Gaucher disease (glucosylceramide accumulation)
  • Lysosomal acid lipase deficiency
• Hartnup disease or other amino‑acid transport defects – rare, but can present with cutaneous plaques.
• Medication‑induced lipid changes – e.g., high‑dose corticosteroids, HIV protease inhibitors, or certain antipsychotics.

Associated Symptoms

The presence of xanthomas often coincides with systemic signs related to the underlying cause. Common associated features include:

• Chest pain or shortness of breath (possible coronary artery disease).
• Abdominal pain, nausea or vomiting – may indicate pancreatitis from very high triglycerides.
• Yellowing of the eyes or skin (jaundice) when liver disease is present.
• Fatigue, weakness, or unintended weight loss.
• Family history of early‑onset heart attacks or strokes.
• Eye changes – especially xanthelasma around the eyelids.
• Joint pain or swelling if tendon xanthomas compress nearby structures.
• Skin itching or irritation from the plaques themselves.

When to See a Doctor

Because xanthomas can be a marker for serious lipid disorders, prompt evaluation is advisable. Seek medical care if you notice any of the following:

• New yellow plaques that are larger than a pinhead, especially on elbows, knees, hands, or around the eyes.
• Rapid increase in size or number of lesions.
• Accompanying symptoms such as chest pain, unexplained fatigue, or abdominal pain.
• Family members with early heart disease (before age 55 in men or 65 in women).
• Any skin changes accompanied by jaundice, fever, or swelling.

Diagnosis

Evaluating a suspected xanthoma involves a combination of visual assessment, laboratory testing, and sometimes imaging.

1. Clinical Examination

• Dermatologist or primary‑care physician inspects the color, texture, and distribution.
• Documentation of size, number, and exact anatomical location.

2. Skin Biopsy (if needed)

• Performed when the appearance is atypical or to rule out mimics such as cutaneous sarcoidosis or malignant lesions.
• Histology shows lipid‑laden macrophages (foam cells) within the dermis.

3. Blood Lipid Panel

• Fasting total cholesterol, LDL‑C, HDL‑C, triglycerides.
• Often repeated on two separate occasions to confirm persistent elevation.

4. Additional Laboratory Tests

• Liver function tests (ALT, AST, alkaline phosphatase, GGT) – screen for cholestasis.
• Fasting glucose and HbA1c – assess for diabetes.
• Genetic testing for FH (LDLR, APOB, PCSK9) if family history is strong.
• Serum apolipoprotein E typing for type III hyperlipoproteinemia.

5. Imaging (if indicated)

• Cardiovascular risk assessment with coronary calcium scoring or carotid ultrasound.
• Abdominal ultrasound or MRI to evaluate for fatty liver or pancreatitis.

Treatment Options

Treatment focuses on two goals: removing or reducing the skin lesions and, more importantly, correcting the underlying metabolic disturbance.

1. Lifestyle Modifications

• Diet: Adopt a heart‑healthy diet low in saturated fats, trans‑fats, and simple sugars. Emphasize:
  • Oily fish (omega‑3 fatty acids) – 2 servings per week.
  • Soluble fiber (oats, barley, legumes) – 25‑30 g/day.
  • Plant sterols/stanols (found in fortified spreads) – 2 g/day.
• Physical activity: At least 150 minutes of moderate‑intensity aerobic exercise weekly.
• Weight management: Achieve a BMI < 25 kg/m² if overweight.
• Alcohol limitation: < 2 drinks per day for men, 1 for women (especially important with high triglycerides).

2. Pharmacologic Therapy

• Statins (e.g., atorvastatin, rosuvastatin) – first‑line for LDL‑cholesterol reduction; can shrink tendon and eruptive xanthomas.
• Ezetimibe – added when LDL goals are not met with statins alone.
• PCSK9 inhibitors (evolocumab, alirocumab) – for severe FH or when statins are insufficient/tolerated.
• Fibrates (fenofibrate, gemfibrozil) – most effective for lowering triglycerides and treating eruptive xanthomas.
• Niacin – useful for raising HDL‑C, but limited by flushing side‑effects; used less often now.
• Omega‑3 fatty‑acid prescription products – 2–4 g EPA/DHA per day for severe hypertriglyceridemia.
• Novel agents: Bempedoic acid, inclisiran (siRNA) in selected patients.

3. Management of Underlying Disease

• For liver disease – treat underlying cholestasis, consider ursodeoxycholic acid for primary biliary cholangitis.
• For diabetes – optimize glycemic control with metformin, GLP‑1 agonists, or insulin as needed.
• For rare storage diseases – enzyme replacement therapy (e.g., imiglucerase for Gaucher disease).

4. Direct Dermatologic Treatments

• Laser therapy (e.g., pulsed‑dye, CO₂ laser) – can shave off superficial plaques when medically indicated.
• Chemical peels or cryotherapy – occasionally used for small, isolated lesions.
• Surgical excision – reserved for large, symptomatic, or cosmetically distressing xanthomas.

5. Monitoring & Follow‑up

• Re‑check lipid panel 4‑12 weeks after initiating or changing therapy, then every 6‑12 months.
• Assess lesion size at each visit; regression is usually seen within months of lipid control.

Prevention Tips

While some genetic forms cannot be prevented, most xanthomas arise from modifiable risk factors.

• Know your numbers: Get a fasting lipid panel every 4‑6 years, or sooner if you have risk factors.
• Maintain a balanced diet rich in fruits, vegetables, whole grains, and healthy fats.
• Stay active – regular exercise improves HDL‑C and lowers triglycerides.
• Avoid tobacco – smoking worsens lipid profiles and accelerates atherosclerosis.
• Control chronic conditions such as diabetes, hypothyroidism, and obesity.
• Limit medications that raise lipids – discuss alternatives with your physician if you are on high‑dose steroids or certain antiretrovirals.
• Family screening: If a close relative has FH or early heart disease, have your lipids checked early in life.

Emergency Warning Signs

If you experience any of the following, seek emergency medical care (call 911 or go to the nearest emergency department):

• Sudden, severe chest pain or pressure that radiates to the arm, neck, or jaw – possible heart attack.
• Profound abdominal pain with vomiting, especially if you have known very high triglycerides – possible pancreatitis.
• Rapid swelling of the face, lips, or tongue accompanied by difficulty breathing – could indicate an allergic reaction to a medication used for lipid control.
• Sudden weakness, numbness, slurred speech, or loss of vision – signs of a possible stroke.

---

**References**

• Mayo Clinic. “Xanthomas: Causes, symptoms, and treatment.” Updated 2023.
• American Heart Association. “Guidelines for the Management of Blood Cholesterol.” 2022.
• National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). “Hyperlipidemia.” 2022.
• Cleveland Clinic. “Familial Hypercholesterolemia.” 2023.
• World Health Organization. “Non‑communicable diseases: risk factor country profiles.” 2021.

```